LauriceGeel
Posted - 6 hours ago
$NVS $TM AITX looks much steadier compared to KSCP’s volatile management decisions.
cielo1
Posted - 1 day ago
$IFRX How does Cosentyx stack up against IFX-1? $NVS COSENTYX is the first biologic treatment of its kind to treat HS by specifically targeting and blocking IL-17A, a molecule that is thought to play a role in causing inflammation that may contribute to HS symptoms.
WeeklyTrader
Posted - 2 days ago
What’s your strategy for $NVS? RSI: 55.5% 50-day MA: $115.57 200-day MA: $105.86
WeeklyTrader
Posted - 2 days ago
What's your prediction for $NVS's next move? RSI: 55.5% 50-day MA: $115.57 200-day MA: $105.86
GioWave
Posted - 4 days ago
@Hatrak1 Careful. Novartis Venture Fund IPOs are completely independent entities with their own tickers. Those IPOs are standalone; they do not report into $NVS ticker.
GioWave
Posted - 4 days ago
@Hatrak1 $NVS past 10 year CAGR is roughly half of the S&P500. Their forward looking growth is on the single digits, highly dependent on weak/old patents.
WeeklyTrader
Posted - 5 days ago
To infinity and beyond, $NVS!
AshHydrogen
Posted - 5 days ago
$PLTR $nvs is CRUSHINH IT WITH PALANTIR!!! Vas from Novartis loves Palantir!!!
Framework
Posted - 1 week ago
Judo Bio launches with $100M for kidney-targeted siRNA therapies – Endpoints News $NVS https://endpts.com/judo-bio-launches-with-100m-for-kidney-targeted-sirna-therapies/
GioWave
Posted - 1 week ago
$NVS might seem undervalued, but there are some red flags to consider: 1. Lack of disclosure on insider trading activity 2. Institutional ownership is just 7%, compared to 70%+ for other drug manufacturers 3. Sales are down 8.23% Y/Y (TTM) 4. Long-term growth remains in the low single digits 5. Heavy reliance on the weak EU/German market 6. Weak patent pipeline 7. Breaking its April-Aug 2024 price pattern
clan
Posted - 1 week ago
$MNKD 🤭 # $NVS $LLY $ASTRAZEN.NSE
NetworkNewsWire
Posted - 1 week ago
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More $ANVS $JNJ $NVS $MRK $GSK https://ibn.fm/5M5mH
AshHydrogen
Posted - 1 week ago
$PLTR helped $nvs to do a $15 BILLION BUYBACK!!! Organized all their data into one data lake and then used PALANTIR ONTOLOGY TO MAKE USE OF THE DATA!!! Why not $msft $nvda $amzn ??? https://sih-st-charts.stocktwits-cdn.com/fit-in/300x0/filters:quality(75)/production/original_587326414.jpeg
ChristaBoarts
Posted - 1 week ago
$NVS is pioneering innovative treatments across various therapeutic areas, maintaining a strong pipeline of breakthrough drugs. Powered by FAAS.
Donovanvick
Posted - 1 week ago
Top oversold mega caps 1. $NVO 2. $ADBE 3. $LLY 4. $NVS 5. $SHEL All in tomorrow
firetypecracker
Posted - 09/29/24
Breakthroughs in Mental Health Treatment with Dr. Drew $CYBN $JNJ $NVS $AZN https://www.youtube.com/watch?v=dwisacHX1XA
AshHydrogen
Posted - 09/29/24
$PLTR Warren you are losing Billions per year dragging your feet on Palantir!!! Your NEBRASKA HOSPITAL SIGNED WITH PALANTIR LAST WEEK!!! $BRK.A SHAREHOLDERS??? $bp is saving Billions per year!!! $TSN is saving millions!!! Coles is saving $1 billion!!! $nvs is doing a $15 billion BUYBACK!!! ALL THANKS TO PALANTIR!!! https://sih-st-charts.stocktwits-cdn.com/production/original_587336450.jpg
souldout
Posted - 09/27/24
$BMY PRTC on London Stock Exchange Only 360m m/c Boom first schizophrenia drug FDA $LLY $MRK $NVS
Pitbowl
Posted - 09/26/24
$MDT $MRK $NVS $PFE Overall Sentiment: GDP data was mixed... the U.S. economy continues to display a predominantly bearish outlook, driven by rising interest rates, contraction in manufacturing, and softening labor data. Though durable goods excluding transportation show core demand resilience, broader economic risks remain. Consumer activity remains strong in some areas, yet housing, manufacturing, and labor market weaknesses raise concerns of further deceleration.
Pitbowl
Posted - 09/25/24
$MDT $MRK $NVS $PFE The U.S. economy currently displays a predominantly bearish sentiment, characterized by tightening lending practices, inflationary pressures, and risks within the real estate and banking sectors. Key indicators show stable core inflation and moderate year-over-year inflation, while labor market data reveals slowing job growth. Manufacturing indices indicate contraction, with both the NY Empire Index and Philly Fed Index signaling economic softness. Consumer activity shows mixed signals, with strong personal spending but disappointing retail sales in August. Additionally, broader economic risks, including deflation and a stronger dollar, exacerbate market uncertainties. Overall, the economic data yields a score of 51 points bearish and 14 points bullish, highlighting a cautious outlook amid rising interest rates and geopolitical uncertainties. Tradingeconomics.com/calendar
Himel92
Posted - 09/24/24
The Last month Performance for $NVS Opening Price: $118.69
Closing Price: $116.37
Highest Price: $120.92
Lowest Price: $113.82
Percentage Change: -1.95% Data analyst: AITX
Biotech2424
Posted - 09/23/24
$50k for 1 dose of Lutathera. That’s how monopar’s drug would be priced. Insane upside in mnpr-101-Lu $MNPR $CATX $ATNM $NVS
NotRichardXRMoron
Posted - 09/21/24
$BCTX $1B $JNJ $2B $NVS
Biotech2424
Posted - 09/20/24
Same radionucleotide as the 2 major blockbusters at Novartis in drug at Monopar.
Lutetium-177
$MNPR $XCUR $CATX $NVS
investor102
Posted - 09/20/24
Below are three companies similar to $BCTX, all valued over $1B. In no world is this company worth less than $1B. Ambrx Biopharma sold to $JNJ for $2B, company focused on engineered antibody drugs for cancer therapies. Ambrx hadn’t enrolled into a Phase 3 trial yet. Mariana Oncology sold to Novartis $NVS for $1.75B if all future milestones are met. Marina Oncology was a preclinical company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient needs. Mirati Therapeutics sold to Bristol Myers Squibb $BMY for $4.8B. Mirati had an approved treatment for lung cancer (Krazati) as well as multiple active clinical trials. https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-to-transform-the-treatment-of-cancer
https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline
scriptstrend2024
Posted - 09/20/24
$NVS OR $PFE would also be smart to acquire Esperion $ESPR . NEXLIZET is going to take 20% at minimum from the EZETIMIBE 8 million yearly scripts because NEXLIZET is twice as effective in lowering cholesterol. Americans are becoming more concerned with statin side effects and type 2 diabetes. A buyout offer could happen anytime. Esperion a $333 million valuation is really a joke, the $900 million milestones and royalties on top should have Esperion valued at $800 million at minimum right now.
Bdawg111
Posted - 09/20/24
$LEN $NVS $PC $PLTR $TSN it’s so obvious too…if Cramer truly doesn’t see it maybe it’s time for him to retire?
AshHydrogen
Posted - 09/20/24
$PLTR this is what Cramer should be telling his audience…PALANTIR HAS THE ONLY AI PLATFORM THAT WORKS!!! How can his audience ever forgive him??? May letter to SHAREHOLDERS!!! $len saved $500,000,000! $TSN saved $700,000,000! $nvs saved $1,000,000,000+++!!! $PC saved $300,000,000!!! Coles saved $1,000,000,000!!! Ask the Russians??? Ask Microsoft???
clan
Posted - 09/20/24
@unopercent ...and Mannkind (MNKD) with its profitable inhalable drugs. $NVS $MRK $SNY